ipl-logo

Albumin-Bound Formulations

1046 Words5 Pages

Albumin-bound formulations Abraxane was the first albumin-bound chemotherapeutic agent to get FDA approval. It contained PTX (a taxane) non-covalently bound to nano-albumin (nab), and was prepared by homogenization of PTX in association with human serum albumin. Multiple PTX molecules (hydrophobic in nature) were bound to each nab. Preclinical studies (in rats) showed equivalent efficacy and improved safety when compared with Taxol (PTX formulation in Cremophor solvent). Clinical trials of Abraxane comparing to Taxol, showed a tolerable dose 50% larger than Taxol and improved tumor response in patients. Abraxane got approval for breast cancer and; later in 2012 and 2013; it was approved for Non-Small Cell Lung Cancer (NSCLC) and pancreatic carcinoma, respectively [82]. …show more content…

Working on the success of Abraxane, nab-rapamycin was also prepared. Rapamycin (also known as sirolimus) works by inhibiting the signals from intracellular kinase (mTOR) which further inhibits cell proliferation. Rapamycin also had poor solubility similar to PTX hence, nab rapamycin was prepared to overcome this barrier and increase its efficacy. The nanoformulation proved to be efficacious in preclinical studies (breast tumor xenograft model) and the drug (ABI-009) is undergoing Phase I-III trials in humans for multiple carcinomas including advanced sarcoma, advanced malignant perivascular epithelioid cell tumor, non muscle invasive bladder cancer and recurrent or refractory solid tumors [82,

Show More
Related
202 Words | 1 Pages

C4564 Description: IC50: 3-AP is a ribonucleotide reductase inhibitor and iron chelator with antitumor activity. Ribonucleotide reductase, the rate-limiting enzyme for de novo DNA synthesis, is an excellent target for chemotherapy. Its increased activity in cancer cells is associated with malignant transformation and proliferation.

Read More
215 Words | 1 Pages

SRT1720 Description: EC50: 0.16 μM SRT1720 is a selective activator of SIRT1. Previous in vitro and in vivo studies using various cancer cell models show the role of SIRT1 either as an oncogene or a tumour suppressor gene. The oncogenic potential of SIRT1 is exemplified by studies indicating that blockade of SIRT1, like other HDACs, triggers growth arrest and apoptosis in breast, colon and lung cancers.

Read More
139 Words | 1 Pages

The blood brain barrier’s main goal is to protect the brain from toxic agents. By doing this, it can interrupt or block the delivery of therapeutic drugs to our brain. Many trials have been attempted to try and force the transport of drugs across the BBB, but some of these ways can structurally damage the BBB. The ideal goal would be to find a way to control the transport drugs across the barrier, but not damaging it at the same time. The most ideal approach found for this goal was “nanobiotechnology-based” delivery.

Read More
758 Words | 4 Pages

Drugs bound to protein are not able to be excreted by the body because it doesn’t filter into the glomerular tubule and this is mainly because of its large size. In this lab the experimental value for binding of acetaminophen to serum albumin was calculated to be 21.93%. The binding of different drugs differ greatly in their ability to bind to serum proteins. One major problem in performing this experiment was that the plasma was contaminated with mint wax-dental floss that was used to tie the ends of the dialysis tube. This affected the absorbance reading of the plasma sample and therefore we had to use the data of another group whose plasma sample wasn’t as

Read More
387 Words | 2 Pages

Grace is a 78-year-old female who is diagnosed with malignant neoplasm of pancreatic duct (C25.3). Grace was previously treated with surgical resection of the distal pancreatectomy, cholecystectomy, splenectomy, and low anterior resection with colorectal ostomy, gemzar, abraxane, cisplatin, opdivo, abemaciclib, galunisertib, but still experienced disease progression. Pathology demonstrates T2, N1, M1 disease with 9 out of 27 lymph nodes remarkable with metastasis to the colon. Your denial indicates that Zejula is not approved for her diagnosis. Zejula therapy is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal

Read More
859 Words | 4 Pages

Clinical trial results Results of a clinical trial involving 173 patients who failed the treatment of Ipilimumab, gave Keytruda its breakthrough designation. Patients were administered a dose of 2 milligrams per kilogram (mg/kg) or a higher dose of 10 mg/kg. It was observed that in nearly 24% of the patients, the tumour had shrunk and this condition lasted from 1.4 to 8.5 months. However, patients with advanced melanoma experienced side effects of the drug which included fatigue, cough, nausea, itchy skin, rash, decreased appetite, constipation, joint pain and diarrhea. 6.

Read More
719 Words | 3 Pages

Recently the plan of treatment for stage IV tumors has changed. Newer forms of targeted drugs and immunotherapy have proven to be more effective than chemotherapy. Immunotherapy drugs such as ipilimumab, pembrolizumab, and nivolumab have been shown to help some people suffering from advanced forms of melanoma live longer, although, some of these drugs have severe side

Read More
188 Words | 1 Pages

By the end of 2003, biotechnology company Genentech was well positioned to deliver on its vision to “be the leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs”. At the time, Genentech had revenues of $3.3 billion and net income of $563 million. Their product sales represented 79% of their revenues, with royalties and contract revenue accounting for the balance. Genentech’s largest revenue-generating product was Rituxan (for non- Hodgkin’s lymphoma) with $1.5 billion in sales.

Read More
367 Words | 2 Pages

A drug designed to treat metastatic melanoma has produced dramatic results in patients with melanoma (Silberman, par.12). J. Leonard Lichtenfeld a medical officer at the American cancer society (Stein, par.8) said “this is a very exciting and important study in a disease that for decades has resisted any meaningful treatment when it has spread through the body” (par.10). Sixty eight thousand Americans are diagnosed with melanoma every year; 8700 are dead from the disease. It is one of deadliest forms of cancer, despite years of research

Read More
404 Words | 2 Pages

In 1946 Mary Lasker and her colleagues revolutionize the Society’s mission and fundraising efforts, helping raise more than $4 million and in 1947 “the first successful chemotherapy treatment for cancer was discovered.”

Read More
1038 Words | 5 Pages

A Word of Conclusion: The statistics mentioned in this piece of writing are not exact but the averages. They do not reflect every patient’s situation. It is the research work carried out by the American Cancer Society.

Read More
234 Words | 1 Pages

Most benign tumors respond well to treatment. However,

Read More
1866 Words | 8 Pages

We also have antibiotics and vaccines to prevent infections (Understanding Animal Research, 2014). According to studies, breast cancer is the most common cancer after non-melanoma skin cancer. The wide range of breast cancer treatments was all discovered and developed through animal testing. Those treatments include surgery, chemotherapy, high-dose x-rays, and hormones such as tamoxifen, Herceptin and aromatase inhibitors (Understanding Animal Research, 2014). Moreover, the development of the heart-lung machine depended heavily on animal testing.

Read More
807 Words | 4 Pages

Non-small cell cancer is common and about 200,000 to 3 million people get in the US each year. Small cell cancer is rarer than non-small, but 20,000 to 200,000 people get in the US each year. The symptoms of these cancers are pain in the back or chest, coughing blood, shortness of breath, wheezing, whole body feeling weak, fatigue, and weight loss. Mostly people aged 60+ are affected the most.

Read More
1330 Words | 6 Pages

It might not cure cancer but maybe in the near future it might surprise

Read More

More about Albumin-Bound Formulations

Related Topics

Open Document